(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

CORRECTED VERSION

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
01 April 2021 (01.04.2021)

WIPO | PCT

(10) International Publication Number
WO 2021/058754 A8

(51) International Patent Classification:
A61P 35/00 (2006.01) *A61K 31/402* (2006.01)
C07D 207/33 (2006.01) *A61K 31/4439* (2006.01)
C07D 231/12 (2006.01) *A61K 31/42* (2006.01)
C07D 261/08 (2006.01) *A61K 31/415* (2006.01)
C07D 401/04 (2006.01) *A61K 31/496* (2006.01)
C07D 405/14 (2006.01) *A61K 31/5377* (2006.01)
C07D 409/04 (2006.01)

(21) International Application Number:
PCT/EP2020/076933

(22) International Filing Date:
25 September 2020 (25.09.2020)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1913921.1 26 September 2019 (26.09.2019) GB

(71) Applicant: **SENTINEL ONCOLOGY LIMITED** [GB/GB]; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB).

(72) Inventors: **BOYLE, Robert George**; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **MAJOR, Meriel Ruth**; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **TRAVERS, Stuart**; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **WALKER, David Winter**; 181 Science Park, Milton Road, Cambridge Cambridgeshire CB4 0GJ (GB). **CZYZEWSKI, Michal**; Onyx

(54) Title: PHARMACEUTICAL COMPOUNDS



(2A)



(2B)



(1A)



(1B)

(57) Abstract: The invention provides a composition of matter which: • (i) consists of at least 90 % by weight of an atropisomer (2A) and 0-10 % by weight of an atropisomer of formula (2B); or • (ii) consists of at least 90 % by weight of an atropisomer (2B) and 0-10 % by weight of an atropisomer of formula (2A); wherein the atropisomer of formula (2A) and the atropisomer of formula (2B) are represented by: formula (2A) and formula (2B) or are pharmaceutically acceptable salts or tautomers thereof, wherein ring X is a benzene or pyridine ring; ring Y is selected from a benzene ring, a pyridine ring and a thiophene ring; R^1 is trifluoromethyl; R^2 is hydrogen; R^3 is hydrogen; m is 0 or 1; n is 0, 1 or 2; Ar^1 is a monocyclic aromatic ring selected from benzene and pyridine; each monocyclic aromatic ring being unsubstituted or substituted with 1 or 2 substituents R^5 as defined herein;

[Continued on next page]

WO 2021/058754 A8

Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB). **LONDESBROUGH, Derek John**; Onyx Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB). **NORTHEN, Julian Scott**; Onyx Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB). **SANTONI, Stefania**; Onyx Scientific, Units 97-98, Silverbriar, Sunderland Enterprise Park East, Sunderland Tyne and Wear SR5 2TQ (GB).

(74) **Agent: HUTCHINS, Michael Richard**; Schlich, 9 St. Catherine's Road, Littlehampton West Sussex BN17 5HS (GB).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *with international search report (Art. 21(3))*

(48) Date of publication of this corrected version:
04 November 2021 (04.11.2021)

(15) Information about Correction:
see Notice of 04 November 2021 (04.11.2021)

and R^4; R^5 when present, R^6 and R^7 independently selected from various substituents as defined herein. Also provided are individual atropisomers thereof as well as of various compounds having a five-membered heteroaromatic ring containing 1 or 2 nitrogen atoms or 1 nitrogen and 1 oxygen atom, with three rings Ar1, X and Y, and substituents R1-R7 all being defined as in formulas (1A) or (1B) below; pharmaceutical compositions and the uses of the atropisomers and compositions are inhibitors of PLK1- and PLK4 kinases, for example in the treatment of cancers. Formula (1A), formula (1B).